{"transactions":[{"id":2070852,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T16:32:05.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date."}],"balance_after":15000,"derivative":{"exercise_price":47.95,"expiration_date":"2032-12-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-000964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919123000964/doc4.xml","form_type":"4"}},{"id":2164742,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-09-07T16:35:17.000Z","date":"2022-09-02","kind":"tax_withholding","acquired":false,"shares":865,"price":26.38,"value":22818.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units."}],"balance_after":13822,"source":{"system":"sec-edgar","filing":"0001209191-22-049023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122049023/doc4.xml","form_type":"4"}},{"id":2175526,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-08-24T16:47:25.000Z","date":"2022-08-22","kind":"sale","acquired":false,"shares":3000,"price":25.9283,"value":77784.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $25.685 to $26.09. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":14687,"source":{"system":"sec-edgar","filing":"0001209191-22-047354","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122047354/doc4.xml","form_type":"4"}},{"id":2200571,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-07-29T17:03:02.000Z","date":"2022-07-27","kind":"sale","acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":17687,"source":{"system":"sec-edgar","filing":"0001209191-22-043547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122043547/doc4.xml","form_type":"4"}},{"id":2203610,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-07-22T17:11:08.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":20687,"source":{"system":"sec-edgar","filing":"0001209191-22-043024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122043024/doc4.xml","form_type":"4"}},{"id":2257434,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-05-25T16:24:56.000Z","date":"2022-05-23","kind":"sale","acquired":false,"shares":3000,"price":26.2235,"value":78670.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $25.72 to $26.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022."}],"balance_after":23687,"source":{"system":"sec-edgar","filing":"0001209191-22-031865","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122031865/doc4.xml","form_type":"4"}},{"id":2290642,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-04-26T17:18:36.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":25125,"source":{"system":"sec-edgar","filing":"0001209191-22-025654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122025654/doc4.xml","form_type":"4"}},{"id":2319334,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-03-24T18:05:46.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001209191-22-020962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122020962/doc4.xml","form_type":"4"}},{"id":2336656,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-03-14T17:03:17.000Z","date":"2022-03-10","kind":"sale","acquired":false,"shares":6000,"price":25,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":31125,"source":{"system":"sec-edgar","filing":"0001209191-22-018522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122018522/doc4.xml","form_type":"4"}},{"id":2351664,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T20:53:06.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter."}],"balance_after":60000,"derivative":{"exercise_price":24.79,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-22-016522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122016522/doc4.xml","form_type":"4"}},{"id":2351663,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2022-03-04T20:53:06.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter."}],"balance_after":37125,"source":{"system":"sec-edgar","filing":"0001209191-22-016522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919122016522/doc4.xml","form_type":"4"}},{"id":2456554,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-12-30T16:36:21.000Z","date":"2021-12-29","kind":"sale","acquired":false,"shares":6000,"price":25,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":27125,"source":{"system":"sec-edgar","filing":"0001209191-21-071604","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121071604/doc4.xml","form_type":"4"}},{"id":2527579,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-11-03T17:55:01.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":33125,"source":{"system":"sec-edgar","filing":"0001209191-21-062762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121062762/doc4.xml","form_type":"4"}},{"id":2560470,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-09-24T17:04:48.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":5307,"price":25.1977,"value":133724.1939,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $25.00 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,841 shares acquired under the Employee Stock Purchase Plan on May 17, 2021."}],"balance_after":36125,"source":{"system":"sec-edgar","filing":"0001209191-21-057651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121057651/doc4.xml","form_type":"4"}},{"id":2754959,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-07T21:17:52.000Z","date":"2021-04-05","kind":"other","acquired":false,"shares":7611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of the date of transfer, the shares subject to the option representing the reporting person's remaining economic interest will vest in monthly installments with respect to 617 shares from May 1, 2021 to January 1, 2023."}],"balance_after":22027,"derivative":{"exercise_price":2.03,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":7611},"source":{"system":"sec-edgar","filing":"0001209191-21-025999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025999/doc4.xml","form_type":"4"}},{"id":2754958,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-07T21:17:52.000Z","date":"2021-04-05","kind":"other","acquired":false,"shares":21871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the date of transfer, the shares subject to the option representing the reporting person's remaining economic interest will vest in monthly installments with respect to 1,459 shares from April 24, 2021 to July 24, 2022."}],"balance_after":48197,"derivative":{"exercise_price":2.03,"expiration_date":"2028-07-23","underlying":"Common Stock","underlying_shares":21871},"source":{"system":"sec-edgar","filing":"0001209191-21-025999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025999/doc4.xml","form_type":"4"}},{"id":2754957,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-07T21:17:52.000Z","date":"2021-04-05","kind":"other","acquired":false,"shares":14253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option representing the reporting person's remaining economic interest are fully vested and exercisable."}],"balance_after":7173,"derivative":{"exercise_price":1.79,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":14253},"source":{"system":"sec-edgar","filing":"0001209191-21-025999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025999/doc4.xml","form_type":"4"}},{"id":2754956,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-07T21:17:52.000Z","date":"2021-04-05","kind":"other","acquired":false,"shares":4168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option representing the reporting person's remaining economic interest are fully vested and exercisable."}],"balance_after":4168,"derivative":{"exercise_price":0.8,"expiration_date":"2026-04-19","underlying":"Common Stock","underlying_shares":4168},"source":{"system":"sec-edgar","filing":"0001209191-21-025999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025999/doc4.xml","form_type":"4"}},{"id":2754955,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-04-07T21:17:52.000Z","date":"2021-04-05","kind":"other","acquired":false,"shares":38308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings."}],"balance_after":39591,"source":{"system":"sec-edgar","filing":"0001209191-21-025999","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025999/doc4.xml","form_type":"4"}},{"id":2756275,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-06T20:06:46.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":40000,"derivative":{"exercise_price":20.93,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-025761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121025761/doc4.xml","form_type":"4"}},{"id":2790430,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T16:29:25.000Z","date":"2021-03-11","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter."}],"balance_after":21426,"derivative":{"exercise_price":1.79,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-020468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121020468/doc4.xml","form_type":"4"}},{"id":2790429,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-03-15T16:29:25.000Z","date":"2021-03-11","kind":"sale","acquired":false,"shares":2500,"price":25,"value":62500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":77899,"source":{"system":"sec-edgar","filing":"0001209191-21-020468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121020468/doc4.xml","form_type":"4"}},{"id":2790428,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-03-15T16:29:25.000Z","date":"2021-03-11","kind":"exercise","acquired":true,"shares":2500,"price":1.79,"value":4475.0,"ownership":{"direct":true},"balance_after":80399,"source":{"system":"sec-edgar","filing":"0001209191-21-020468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121020468/doc4.xml","form_type":"4"}},{"id":2860864,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-16T19:46:05.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter."}],"balance_after":23926,"derivative":{"exercise_price":1.79,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-011013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121011013/doc4.xml","form_type":"4"}},{"id":2860863,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-02-16T19:46:05.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":316,"price":27.27,"value":8617.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $27.22 to $27.315. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":77899,"source":{"system":"sec-edgar","filing":"0001209191-21-011013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121011013/doc4.xml","form_type":"4"}},{"id":2860862,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-02-16T19:46:05.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":2184,"price":26.56,"value":58007.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $25.97 to $26.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":78215,"source":{"system":"sec-edgar","filing":"0001209191-21-011013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121011013/doc4.xml","form_type":"4"}},{"id":2860861,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-02-16T19:46:05.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":2500,"price":1.79,"value":4475.0,"ownership":{"direct":true},"balance_after":80399,"source":{"system":"sec-edgar","filing":"0001209191-21-011013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121011013/doc4.xml","form_type":"4"}},{"id":2910063,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-12T21:43:01.000Z","date":"2021-01-11","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter."}],"balance_after":26426,"derivative":{"exercise_price":1.79,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-003345","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121003345/doc4.xml","form_type":"4"}},{"id":2910062,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-01-12T21:43:01.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":1527,"price":26.74,"value":40831.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $26.35 to $27.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":77899,"source":{"system":"sec-edgar","filing":"0001209191-21-003345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121003345/doc4.xml","form_type":"4"}},{"id":2910061,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-01-12T21:43:01.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":973,"price":25.38,"value":24694.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":79426,"source":{"system":"sec-edgar","filing":"0001209191-21-003345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121003345/doc4.xml","form_type":"4"}},{"id":2910060,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":121083,"kind":"person","name":"Sauer Paul","position":1,"cik":"0001813796","reported_name":"Sauer Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Process Dev, Manufacturing"}}],"security":"Common Stock","published_at":"2021-01-12T21:43:01.000Z","date":"2021-01-11","kind":"exercise","acquired":true,"shares":2500,"price":1.79,"value":4475.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,284 shares acquired under the Employee Stock Purchase Plan on November 17, 2020."}],"balance_after":80399,"source":{"system":"sec-edgar","filing":"0001209191-21-003345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813796/000120919121003345/doc4.xml","form_type":"4"}}]}